Why MGRC
Overview
Founded in 2004, Malaysian Genomics Resource Centre (MGRC) is a pioneering biotechnology company listed on Bursa Malaysia, with a proven track record in genomics and regenerative medicine.
We began as one of the region’s earliest providers of bioinformatics and genome analysis, and have since evolved into a leader in personalised healthcare — offering a comprehensive range of genetic tests, contract R&D services, and advanced cell-based therapies.
Our offerings include precision genetic screening, project-based analysis, and high-quality cell therapy and cosmeceutical products — all developed and processed in our certified laboratories to meet the highest industry standards.
With decades of scientific expertise and collaborations with leading institutions around the world, MGRC is committed to advancing healthcare through innovation — delivering solutions that are tailored, reliable, and built for the future of medicine.
What Sets Us Apart
Empowering Health, Enhancing Lives
Our mission is to improve quality of life through science-backed, accessible, and future-forward health innovations.
Vision
To be Asia’s leading innovator in genomics, regenerative medicine, and immunotherapy—improving lives through the science of tomorrow.
Mission
To deliver world-class, personalised healthcare solutions through cutting-edge biotechnology, anchored in safety, integrity, and scientific excellence.
Our Milestones
Foundation
Founded as Malaysian Genomic Resource Centre (MGRC), marking the start of our pioneering work in genomics.
Global Genome Breakthrough
Achieved a global milestone by completing the world’s largest genome assembly of the oil palm in collaboration with Sime Darby.
Public Listing
Listed on the ACE Market of Bursa Malaysia Securities Berhad, opening a new chapter in our corporate growth.
Innovation in Genetic Testing
Launched Dtect, expanding into advanced genetic testing (screening) solutions.
Strategic Expansion
Acquired 100% of Clinipath Pathology, strengthening our position in diagnostic services.
Refocusing for Growth
Divested Clinipath Pathology to unlock capital for strategic investment into immunotherapy innovations.
Expansion into Advanced Cellular Immunotherapy
Diversified into CAR T-Cell technology, expanding our footprint in cutting-edge cell therapy.
National Health Contribution
Partnered with Pharmaniaga to distribute COVID-19 vaccines across Malaysia, contributing to national health efforts.
Stem Cell Advancements
Awarded the COVID-19 Surveillance Contract by the Institute for Medical Research. Expanded capabilities into Mesenchymal Stem Cells (MSC) and exosomes.
Genetic Solutions Launch
Launched Fertility GeneCode and MyGeneCode. Formed partnerships, including collaboration with Kuala Lumpur City Hall.
Wellness & Research Milestones
Strengthened university-industry collaborations with the University of Malaya and UPM. Advanced research into Natural Killer T (NKT) Cells and began NIPT (Non-Invasive Prenatal Testing) services.
Next-Generation Immunology
Set to launch the NK Activity Test, continuing our commitment to innovative health solutions.
Our Milestones
2004
Incorporation of Malaysian Genomics Resource Centre Berhad (MGRC)
Established as a pioneer in genome sequencing and bioinformatics.
2010
Listed on ACE Market of Bursa Malaysia
Became one of the first biotechnology companies to go public in Malaysia.
2012
Proprietary Dtect® Genetic Screening Tests
Introduced the first suite of preventive genetic tests tailored for Asian populations.
2015
Expanded into Stem Cell Therapies
Introduced Mesenchymal Stem Cell (MSC) and Exosome-based regenerative programs.
2021
Introduced Immunotherapy Services
Launched NK Cell and CAR-T cell programs to support cancer and immune-related treatment options.
2023
Launched Compounding Pharmacy & NAD+ IV Programs
Supporting holistic wellness through precision compounding and anti-aging infusion therapies.
2025
Expanded Internationally with Clinical Collaborations
Strengthened regional footprint through hospital and specialist clinic partnerships across Southeast Asia.